Halozyme Therapeutics, Inc. filed a Form 8-K on August 18, 2026, disclosing that Dannielle Appelhans was elected to its Board of Directors on August 14, 2026.

Key Highlights

  • New director elected: Dannielle Appelhans joined the Halozyme Therapeutics Board of Directors on August 14, 2026.
  • Director class: Ms. Appelhans was elected to the class of directors with terms ending at the annual meeting of stockholders in 2028.
  • No committee assignment: According to the filing, Ms. Appelhans was not initially assigned to any Board committee.
  • Compensation terms: Ms. Appelhans will receive compensation under the non-employee director compensation program, which currently consists of cash retainers, restricted stock, and stock option awards.
  • No special arrangements: The filing states there are no arrangements or understandings pursuant to which Ms. Appelhans was elected, and no related person transactions between the company and Ms. Appelhans.

Halozyme Adds Dannielle Appelhans to Its Board of Directors

Halozyme Therapeutics, Inc. (NASDAQ:HALO) reported via an Item 5.02 disclosure that Dannielle Appelhans was elected to the company's Board of Directors on August 14, 2026. The filing, signed by Executive Vice President, General Counsel and Corporate Secretary Mark Snyder, was submitted to the SEC on August 18, 2026.

According to the filing, Ms. Appelhans was placed in the class of directors whose terms expire at the company's annual meeting of stockholders in 2028. The filing notes she was not initially assigned to any Board committee. Her compensation will follow the standard non-employee director compensation program applicable to all non-employee directors, which the company described as currently consisting of cash retainers for Board and committee service, restricted stock awards, and stock option awards, as revised from time to time. The filing referenced the proxy statement for the 2026 Annual Meeting of Stockholders, held on May 5, 2026, as the source describing the current components of that program.

The filing explicitly states that "there are no arrangements or understandings pursuant to which Ms. Appelhans was elected as a director and there are no related person transactions between the Company and Ms. Appelhans."

What Was Disclosed

Halozyme Therapeutics disclosed the election of Dannielle Appelhans to its Board of Directors, her director class assignment through 2028, her compensation terms under the existing non-employee director program, and confirmed no special arrangements or related party transactions.